0 results available. Select is focused ,type to refine list, press Down to open the menu,
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. It is developing givastomig, a bispecific antibody, which is in Phase 1...
The following section summarizes insights on I Mab's Fair Value (FINBOX):
We've identified the following companies as similar to I Mab because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Fair Value (FINBOX) in the predictions category include:
The Fair Value is an estimation determined through various valuation models, including discounted cash flow analysis, peer valuation multiples models,...
Fair Value represents the fair value estimated using our valuation models.
The chart above depicts the distribution of fair value (finbox) for companies operating in the Healthcare sector in the Developed economic region. Over 2,310 companies were considered in this analysis, and 2,224 had meaningful values. The average fair value (finbox) of companies in the sector is 12.35 with a standard deviation of 29.17.
I Mab's Fair Value (FINBOX) of 1.29 ranks in the 41.6% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 2,315 |
| Included Constituents | 2,224 |
| Min | 0.0034 |
| Max | 220.42 |
| Median | 2.04 |
| Mean | 12.35 |
| Standard Deviation | 29.17 |
You can find companies with similar fair value (finbox) using this stock screener.